AU2021331854B2 — Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
Assigned to Daewoong Pharmaceutical Co Ltd · Expires 2025-03-13 · 1y expired
What this patent protects
The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, a composition containing a drug is mixed and formulated in a single compartment form, and thus the stability and u…
USPTO Abstract
The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, a composition containing a drug is mixed and formulated in a single compartment form, and thus the stability and uniform dissolution rate of the drug are ensured, thereby simplifying the manufacturing process and allowing the process cost to be reduced, and allowing a bioequivalent formulation as compared to a conventional single formulation to be obtained.
Drugs covered by this patent
- Caprelsa (VANDETANIB) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.